Biosimilars

Dr Kashyap Patel: The Pros and Cons of Pegfilgratim Biosimilars vs Neulasta Onpro

September 17th 2021, 3:36pm

Video

Cost and lack of insurance are big drivers of why a physician may choose to prescribe a pegfilgrastim biosimilar over the convenient on-body device for the originator, said Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care Associates.

Samsung Bioepis Releases Positive 5-Year Follow-up Results for Trastuzumab Biosimilar

September 15th 2021, 1:00pm

Article

Samsung Bioepis found during a 5-year follow-up study that Ontruzant, the company’s trastuzumab biosimilar, had comparable cardiac safety and long-term efficacy with the reference product Herceptin.

Dr Kashyap Patel Highlights How the Pandemic Influenced Utilization of Pegfilgrastim Biosimilars

September 10th 2021, 8:09pm

Video

Reducing the risks of secondary neutropenia, exposure to COVID-19, mortality, and financial toxicity were all major reasons the use of pegfilgrastim biosimilar gained traction during the pandemic, said Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care.

Sandoz, Bio-Thera Solutions Enter Deal to Commercialize Avastin Biosimilar

September 10th 2021, 1:52pm

Article

Bio-Thera Solutions and Sandoz have partnered for to allow for the commercialization of BAT1706, a bevacizumab biosimilar referencing Avastin, for the treatment of several forms of cancer.

Dr Neal Dave Expresses Excitement for the First PD-1 Inhibitor Biosimilar

September 3rd 2021, 12:15pm

Video

Neal Dave, PharmD, the executive director of pharmacy at Texas Oncology, discussed physician anticipation for the first biosimilars for programmed death (PD)-1 inhibitors.

Saudi Researchers Call for Greater Use of Trastuzumab Biosimilars to Offset Breast Cancer Costs

September 2nd 2021, 10:31pm

Article

Switching from Herceptin (reference trastuzumab) to trastuzumab biosimilars could significantly reduce direct medication costs attributed to breast cancer management in Saudi Arabia, researchers concluded.

Dr Neal Dave: Are Physicians Excited for More Biosimilars to Enter the Oncology Space?

August 27th 2021, 7:15pm

Video

Neal Dave, PharmD, the executive director of pharmacy at Texas Oncology, talks about the anticipation for more biosimilars to enter the oncology market and the current level of interest in the pipeline.

Study Confirms Overall Survival in DLBCL Is Comparable Between Rituximab Biosimilars and Rituxan

August 24th 2021, 1:23pm

Article

In comparison with reference rituximab (Rituxan), the use of rituximab biosimilars in combination therapy produced similar 3-year overall survival among patients with large-B-cell lymphoma (DLBCL), investigators concluded.

Site of Care Potentially Limits Cost Savings From Biosimilars

August 23rd 2021, 1:00pm

Article

Although previous work has found lower costs for biosimilar filgrastim compared with reference filgrastim, this study found that site of care can change this calculus, reducing savings.

Dr Neal Dave Explains Why Biosimilars Should Be Favored Over Reference Products

August 20th 2021, 1:30pm

Video

Neal Dave, PharmD, the executive director of pharmacy at Texas Oncology, discusses the potential for biosimilar utilization to grow and the reasons why his practice favors them over reference products.